[ Price : $8.95]
FDA reminds patients and healthcare providers about risks associated with recalled Exactech replacement joint devices that were pa...[ Price : $8.95]
Regeneron and Sanofi say an investigational Phase 3 trial of Dupixent in some COPD patients met all key primary and secondary endp...[ Price : $8.95]
The Government Accountability Office reports on regenerative medicine and advanced therapies workforce and education/training need...[ Price : $8.95]
A new White House Office of Science and Technology Policy (OSTP) report lists 10 bold goals for the U.S. biotechnology and biomanu...[ Price : $8.95]
CDRH director Jeff Shuren tells an Alliance for Stronger FDA Webinar that cybersecurity is one of the biggest concerns that keeps ...[ Price : $8.95]
FDA approves a Cidara Therapeutics and Melinta Therapeutics NDA for Rezzayo (rezafungin for injection) for treating candidemia and...[ Price : $8.95]
The Federal Trade Commission asks the Delaware federal court to consider four antitrust implications in deciding whether to grant ...[ Price : $8.95]
FDA issues AbbVie a complete response letter for ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in adults wit...